Biocryst Pharma Inc (BCRX)

$6.63 +0.05 (0.76%)
Market Cap 1.39B
Revenue (ttm) 450.71M
Net Income (ttm) -88.88M
EPS (ttm) N/A
PE Ratio 83.38
Forward PE 18.42
Profit Margin -19.72%
Debt to Equity Ratio -1.73
Volume 3,721,900
Avg Vol 4,218,570
Day's Range N/A - N/A
Shares Out 210.74M
Stochastic %K 29%
Beta 0.80
Analysts Strong Sell
Price Target $20.60

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phas...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 919 859 1302
Fax: 919 859 1314
Address:
4505 Emperor Boulevard, Suite 200, Durham, United States
joooiink
joooiink Feb. 3 at 5:07 PM
$BCRX
0 · Reply
Paulzk
Paulzk Feb. 3 at 5:03 PM
$BCRX In the same way that the invention of semiconductors made today’s smartphones, computers and electronics possible, topoconductors and the new type of chip they enable offer a path to developing quantum systems that can scale to a million qubits and are capable of tackling the most complex industrial and societal problems, Microsoft said. https://news.microsoft.com/source/features/innovation/microsofts-majorana-1-chip-carves-new-path-for-quantum-computing/
0 · Reply
2YrsEarly
2YrsEarly Feb. 3 at 4:53 PM
$BCRX 2018-2026
0 · Reply
doublebtx
doublebtx Feb. 3 at 4:21 PM
$BCRX Been pinned in basically the same 20 cent range going on 3 weeks now. On the one hand I would hope that is due to some covering finally before moving back in the other direction. On the other hand, I have learned to never get my hopes up here and logic need not apply...
0 · Reply
Paulzk
Paulzk Feb. 3 at 4:18 PM
$BCRX Can't believe how much MSFT has fallen. Perhaps it's the Bill Gates/Epstein effect. Anyway I bought more today. MSFT Filled at $413.565
0 · Reply
buy_undervalued_stocks
buy_undervalued_stocks Feb. 3 at 2:53 PM
$BCRX longs investing here... Buy, hold, get rich!
0 · Reply
Fergus20
Fergus20 Feb. 3 at 1:53 PM
$BCRX but but but the pipeline now!!! When is our pipeline getting priced in? 500 million in sales with the new drug should be a 3 billion dollar increase of market cap. Or about 12 dollars per share plus the 6.50
1 · Reply
Saffier1988
Saffier1988 Feb. 3 at 1:01 PM
$BCRX After R&D day late 2023 the never announced anything about C2 , C5 and Bifunctional complement inhibitor they were all supposed to enter clinic in 2025… there not even mentioned anymore on website anyone know what status is??
2 · Reply
Pharm_Hand
Pharm_Hand Feb. 3 at 12:47 PM
$BCRX $6.66 How fitting for this POS.
0 · Reply
Paulzk
Paulzk Feb. 3 at 9:20 AM
$BCRX https://finance.yahoo.com/news/januarys-jobs-report-to-be-delayed-by-government-shutdown-175359822.html
0 · Reply
Latest News on BCRX
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Jan 23, 2026, 9:00 AM EST - 11 days ago

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:56 PM EST - 21 days ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

Jan 12, 2026, 7:00 AM EST - 22 days ago

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2026, 7:01 AM EST - 4 weeks ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 4 weeks ago

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

FDA expands approval of BioCryst's rare disease drug for use in young children

Dec 12, 2025, 7:06 AM EST - 7 weeks ago

FDA expands approval of BioCryst's rare disease drug for use in young children

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

Dec 12, 2025, 7:00 AM EST - 7 weeks ago

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Dec 3, 2025, 7:00 AM EST - 2 months ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 24, 2025, 2:23 PM EST - 2 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Nov 6, 2025, 8:00 AM EST - 3 months ago

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

BioCryst to Present at Upcoming Investor Conference

Nov 5, 2025, 7:00 AM EST - 3 months ago

BioCryst to Present at Upcoming Investor Conference

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:16 PM EST - 3 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 7:00 AM EST - 3 months ago

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 23, 2025, 7:00 AM EDT - 3 months ago

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Oct 20, 2025, 7:00 AM EDT - 3 months ago

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Oct 17, 2025, 3:20 PM EDT - 3 months ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

ATXS

BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript

Oct 14, 2025, 1:16 PM EDT - 4 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

Oct 14, 2025, 12:20 PM EDT - 4 months ago

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

ATXS

BioCryst to buy Astria Therapeutics in $700 million deal

Oct 14, 2025, 7:35 AM EDT - 4 months ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

Oct 14, 2025, 7:00 AM EDT - 4 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

ATXS

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Oct 1, 2025, 7:00 AM EDT - 4 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

BioCryst: Blue Light Special In Small Cap Biotech Aisle

Sep 29, 2025, 2:53 AM EDT - 4 months ago

BioCryst: Blue Light Special In Small Cap Biotech Aisle

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 5:47 AM EDT - 5 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript

BioCryst Announces Departure of Dr. Helen Thackray

Aug 11, 2025, 7:00 AM EDT - 6 months ago

BioCryst Announces Departure of Dr. Helen Thackray

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 11:38 AM EDT - 6 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 7:00 AM EDT - 6 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 31, 2025, 7:00 AM EDT - 6 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 21, 2025, 7:00 AM EDT - 7 months ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 9, 2025, 7:00 AM EDT - 7 months ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jul 7, 2025, 7:00 AM EDT - 7 months ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 27, 2025, 7:00 AM EDT - 7 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 16, 2025, 7:00 AM EDT - 8 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

ORLADEYO® (berotralstat) Approved in Colombia

Jun 13, 2025, 7:00 AM EDT - 8 months ago

ORLADEYO® (berotralstat) Approved in Colombia

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 6, 2025, 7:00 AM EDT - 8 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

Jun 2, 2025, 7:00 AM EDT - 8 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 30, 2025, 7:00 AM EDT - 8 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

BioCryst to Present at Upcoming Investor Conferences

May 27, 2025, 7:00 AM EDT - 9 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 16, 2025, 7:00 AM EDT - 9 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 14, 2025, 7:00 AM EDT - 9 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

May 5, 2025, 5:29 PM EDT - 9 months ago

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

BioCryst: Strong Opportunity For A Double With A Proven Therapy

May 5, 2025, 2:05 PM EDT - 9 months ago

BioCryst: Strong Opportunity For A Double With A Proven Therapy

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 12:54 PM EDT - 9 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 9 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst Appoints Steve Frank to Board of Directors

May 1, 2025, 7:00 AM EDT - 9 months ago

BioCryst Appoints Steve Frank to Board of Directors

BioCryst to Report First Quarter 2025 Financial Results on May 5

Apr 21, 2025, 7:00 AM EDT - 10 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

BioCryst: Orladeyo's Expansion Is Just Getting Started

Feb 26, 2025, 9:09 AM EST - 1 year ago

BioCryst: Orladeyo's Expansion Is Just Getting Started

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

Feb 26, 2025, 7:45 AM EST - 1 year ago

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

Feb 25, 2025, 6:24 PM EST - 1 year ago

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 12:17 PM EST - 1 year ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

joooiink
joooiink Feb. 3 at 5:07 PM
$BCRX
0 · Reply
Paulzk
Paulzk Feb. 3 at 5:03 PM
$BCRX In the same way that the invention of semiconductors made today’s smartphones, computers and electronics possible, topoconductors and the new type of chip they enable offer a path to developing quantum systems that can scale to a million qubits and are capable of tackling the most complex industrial and societal problems, Microsoft said. https://news.microsoft.com/source/features/innovation/microsofts-majorana-1-chip-carves-new-path-for-quantum-computing/
0 · Reply
2YrsEarly
2YrsEarly Feb. 3 at 4:53 PM
$BCRX 2018-2026
0 · Reply
doublebtx
doublebtx Feb. 3 at 4:21 PM
$BCRX Been pinned in basically the same 20 cent range going on 3 weeks now. On the one hand I would hope that is due to some covering finally before moving back in the other direction. On the other hand, I have learned to never get my hopes up here and logic need not apply...
0 · Reply
Paulzk
Paulzk Feb. 3 at 4:18 PM
$BCRX Can't believe how much MSFT has fallen. Perhaps it's the Bill Gates/Epstein effect. Anyway I bought more today. MSFT Filled at $413.565
0 · Reply
buy_undervalued_stocks
buy_undervalued_stocks Feb. 3 at 2:53 PM
$BCRX longs investing here... Buy, hold, get rich!
0 · Reply
Fergus20
Fergus20 Feb. 3 at 1:53 PM
$BCRX but but but the pipeline now!!! When is our pipeline getting priced in? 500 million in sales with the new drug should be a 3 billion dollar increase of market cap. Or about 12 dollars per share plus the 6.50
1 · Reply
Saffier1988
Saffier1988 Feb. 3 at 1:01 PM
$BCRX After R&D day late 2023 the never announced anything about C2 , C5 and Bifunctional complement inhibitor they were all supposed to enter clinic in 2025… there not even mentioned anymore on website anyone know what status is??
2 · Reply
Pharm_Hand
Pharm_Hand Feb. 3 at 12:47 PM
$BCRX $6.66 How fitting for this POS.
0 · Reply
Paulzk
Paulzk Feb. 3 at 9:20 AM
$BCRX https://finance.yahoo.com/news/januarys-jobs-report-to-be-delayed-by-government-shutdown-175359822.html
0 · Reply
Paulzk
Paulzk Feb. 3 at 9:17 AM
$BCRX A bounce. Gold 4,911.96 +278.08 +6.00% Silver 86.61 +9.44 +12.24%
0 · Reply
Paulzk
Paulzk Feb. 3 at 6:48 AM
$BCRX In contrast to prior sell-offs that signaled a long-term top for precious metals, there's no indication that the trends fueling the run-up are reversing, Deutsche Bank analysts wrote in a Monday note reiterating a $6,000-per-ounce target. https://www.investors.com/news/gold-price-still-may-hit-6000-deutsche-bank-bitcoin-tests-trump-second-term-low/?utm_source=newsshowcase&utm_medium=gnews&utm_campaign=CDAqEAgAKgcICjDOm4YLMJD1gwMw8rzzBA&utm_content=rundown&gaa_at=g&gaa_n=AWEtsqcV7Ll5Q2PbxlJJGyaBGJRKf5IiOt7iXUaCRofR_2OwcdlYZ4YK9zn2zy1v28DNkYQJW6Cz3w%3D%3D&gaa_ts=6981a673&gaa_sig=3iQ9GyYnLoP_7DOb0HBKTcykOe8b2cs-gXeV1PZW0hEIfhMrhe3xf8c4zPCjCctO3fbZsF3YfxBFh8yPTvyNpA%3D%3D
0 · Reply
Paulzk
Paulzk Feb. 3 at 6:44 AM
$BCRX The response to that late-December announcement has been uniform: The companies building each of the projects sued the administration. As of Monday, every single one of them has achieved the same result: a temporary injunction that allows them to continue construction. “If the government’s concern is the operation of these facilities, allowing the ongoing operation of the 44 turbines while prohibiting the repair of the existing turbines and the completion of the 18 additional turbines is irrational,” Judge Brian E. Murphy said. That once again raises the possibility that the order halting construction will ultimately be held to be arbitrary and capricious. https://arstechnica.com/science/2026/02/court-orders-restart-of-all-us-offshore-wind-construction/
0 · Reply
Astronave
Astronave Feb. 2 at 11:08 PM
$BCRX This company doesn't have much else to offer. There are no major surprises. They'll wait for the results of two small trials and then be acquired by a larger company interested in this therapeutic area. The price will be determined by a simple financial calculation with a slight discount. $25 is a good price.
1 · Reply
BillsBowTie
BillsBowTie Feb. 2 at 11:01 PM
$BCRX FWIW - Not expecting much, but Island issued a trading halt today. Some of their past halts were for minor things like insider share sales, but this one looks like it has to do with feedback from the FDA.
1 · Reply
Tim5450
Tim5450 Feb. 2 at 9:07 PM
$BCRX what the fuck are they doing?? Give us an update .
1 · Reply
nowherebutup
nowherebutup Feb. 2 at 8:38 PM
$BCRX
0 · Reply
1point21gigawatts
1point21gigawatts Feb. 2 at 5:17 PM
$BCRX OMG it’s green
2 · Reply
2YrsEarly
2YrsEarly Feb. 2 at 3:37 PM
$BCRX Remember cheerleading starts at $12! That’s only $5.43 away now! 😂
2 · Reply
Iwillbuy
Iwillbuy Feb. 2 at 3:33 PM
$BCRX BOD please for the love of God…..do something here for your longs! Buy back shares or sell the darn company. You said you were going to help investors and be more mindful of shareholders stock value…. You went and did exactly the opposite of what you said during your previous calls…..
1 · Reply
buy_undervalued_stocks
buy_undervalued_stocks Feb. 2 at 2:44 PM
$BCRX Pathetic leadership year after year...
0 · Reply
SCCT2FL
SCCT2FL Feb. 2 at 2:42 PM
$BCRX c-suite performing worse and worse
0 · Reply